ViewRay has announced that Baptist Health South Florida will acquire a second MRIdian MR-guided radiation therapy system, joining other leading institutions from around the globe investing in multiple MRIdian systems. Baptist Health is expanding its MRIdian MR-guided radiation therapy services at Lynn Cancer Institute, part of Baptist Health South Florida. This purchase complements Baptist Health’s current MRIdian program at Miami Cancer Institute which has been using the MR-Linac to treat patients since 2018, and makes Lynn Cancer Institute one of only three cancer centers in South Florida offering the novel technology.
“The addition of a second MRIdian system is an important expansion of our radiation oncology offerings at Lynn Cancer Institute,” said Michael Kasper, M.D., medical director of radiation oncology at Lynn Cancer Institute. “The MRIdian system provides powerful visualization and accurate delivery of radiation through the use of continuous MR-guidance. This type of precision radiation delivery offers not only added patient convenience through shorter radiation courses but also optimized efficacy in cancer care, allowing us to see tumors and normal organs and adapt radiation daily based on their position.”
Lynn Cancer Institute, based at Boca Raton Regional Hospital, is one of the largest cancer centers in South Florida and is accredited as a Comprehensive Cancer Center by the American College of Surgeons. The Lynn Cancer Institute treats an estimated 4,000 newly diagnosed cancer patients each year with multimodality teams who specialize in a specific site of cancer. The team is able to develop standards of care for the specific disease site it treats. These standards reflect the most advanced technology and current treatments available.
“We are pleased to see Baptist Health’s expanded commitment to MRIdian SMART (stereotactic MR-guided adaptive radiotherapy) for patients as part of its oncology therapy solutions,” said Paul Ziegler, chief commercial officer at ViewRay. “As a health system, Baptist Health has a reputation for offering the most innovative treatment options available. The addition of a second MRIdian system further advances their position as a leader in cancer care.”
The MRIdian system provides oncologists outstanding anatomical visualization through diagnostic-quality MR images and the ability to adapt a radiation therapy plan to the targeted cancer with the patient on the table. This combination helps physicians to define tight treatment margins to avoid unnecessary radiation exposure of vulnerable nearby organs-at-risk and allows the delivery of ablative radiation doses in five or fewer treatment sessions, without relying on implanted markers. By providing real-time continuous tracking of the target and surrounding healthy tissues, MRIdian enables automatic gating of the radiation beam if the target moves outside the user-defined margins. This provides for delivery of the prescribed dose to the target, while sparing surrounding healthy tissue and critical structures, which results in minimizing toxicities typically associated with conventional radiation therapy.
Nearly 16,000 patients have been treated with MRIdian SMART (Stereotactic MR-guided Adaptive Radiotherapy). Currently, 46 MRIdian systems are installed at hospitals around the world where they are used to treat a wide variety of solid tumors and are the focus of numerous ongoing research efforts. MRIdian has been the subject of hundreds of peer-reviewed publications, scientific meeting abstracts, and presentations.